Franklin, Tennessee – September 19, 2026 -- Adora Life Science has appointed Dr. Clinton D. Morgan, MD, as its full-time Chief Medical Officer, effective November 1, 2026, the company announced.
Neurosurgeon exits clinical practice to lead human trials for veterinary-derived drug
Dr. Morgan previously served on Adora's Board of Directors and consulted part-time on the company's human therapeutic strategy. In his new role, he will direct Adora's human clinical development, regulatory strategy, and scientific research network, and will chair a newly assembled Scientific Advisory Board spanning glycobiology, osteoarthritis, and radiation injury experts.
Adora targets human applications for a 40-year veterinary arthritis drug
Adora is developing matrix restoration therapeutics based on PSGAG, a chondroitin sulfate-derived biopolymer used for more than four decades in veterinary medicine as a disease-modifying antiarthritic drug. The company states PSGAG works by protecting and restoring extracellular matrix tissue in cartilage, skin, and soft tissue rather than only addressing downstream symptoms of degeneration.
Company holds five US patents protecting PSGAG technology through 2043
Adora was originally founded to develop a veterinary injectable PSGAG generic to Adequan, a disease-modifying antiarthritic drug for equine, canine, and companion animal markets. Research into topical PSGAG dosage forms led the company to expand into human product development. Adora holds five US patents covering PSGAG manufacturing and dosage forms, with protection extending until at least late 2043, and additional patent applications are pending.
CEO cites Morgan's departure from surgical career as validation of strategy
Adora Chairman and CEO Thomas E. D'Ambra said Dr. Morgan's decision to leave a growing medical career to join Adora full time reflects confidence in the company's approach. Dr. Morgan trained at the Barrow Neurological Institute, where he led the Barrow Innovation Center for neurosurgical device development, and authored more than 60 scientific publications before devoting roughly three-quarters of his clinical practice to osteoarthritis and degenerative disc disease.
"Disease modification of arthritis stops the disease in its tracks and makes the operation unnecessary in the first place," Dr. Morgan said, describing the shift from surgical intervention to regenerative glycobiology as the driver behind his move.